Cargando…

Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates

A strategy for the preparation of homogeneous antibody–drug conjugates (ADCs) containing multiple payloads has been developed. This approach utilizes sequential unmasking of cysteine residues with orthogonal protection to enable site‐specific conjugation of each drug. In addition, because the approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Levengood, Matthew R., Zhang, Xinqun, Hunter, Joshua H., Emmerton, Kim K., Miyamoto, Jamie B., Lewis, Timothy S., Senter, Peter D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299463/
https://www.ncbi.nlm.nih.gov/pubmed/27966822
http://dx.doi.org/10.1002/anie.201608292
_version_ 1782506030346797056
author Levengood, Matthew R.
Zhang, Xinqun
Hunter, Joshua H.
Emmerton, Kim K.
Miyamoto, Jamie B.
Lewis, Timothy S.
Senter, Peter D.
author_facet Levengood, Matthew R.
Zhang, Xinqun
Hunter, Joshua H.
Emmerton, Kim K.
Miyamoto, Jamie B.
Lewis, Timothy S.
Senter, Peter D.
author_sort Levengood, Matthew R.
collection PubMed
description A strategy for the preparation of homogeneous antibody–drug conjugates (ADCs) containing multiple payloads has been developed. This approach utilizes sequential unmasking of cysteine residues with orthogonal protection to enable site‐specific conjugation of each drug. In addition, because the approach utilizes conjugation to native antibody cysteine residues, it is widely applicable and enables high drug loading for improved ADC potency. To highlight the benefits of ADC dual drug delivery, this strategy was applied to the preparation of ADCs containing two classes of auristatin drug‐linkers that have differing physiochemical properties and exert complementary anti‐cancer activities. Dual‐auristatin ADCs imparted activity in cell line and xenograft models that are refractory to ADCs comprised of the individual auristatin components. This work presents a facile method for construction of potent dual‐drug ADCs and demonstrates how delivery of multiple cytotoxic warheads can lead to improved ADC activities. Lastly, we anticipate that the conditions utilized herein for orthogonal cysteine unmasking are not restricted to ADCs and can be broadly utilized for site‐specific protein modification.
format Online
Article
Text
id pubmed-5299463
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52994632017-02-22 Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates Levengood, Matthew R. Zhang, Xinqun Hunter, Joshua H. Emmerton, Kim K. Miyamoto, Jamie B. Lewis, Timothy S. Senter, Peter D. Angew Chem Int Ed Engl Communications A strategy for the preparation of homogeneous antibody–drug conjugates (ADCs) containing multiple payloads has been developed. This approach utilizes sequential unmasking of cysteine residues with orthogonal protection to enable site‐specific conjugation of each drug. In addition, because the approach utilizes conjugation to native antibody cysteine residues, it is widely applicable and enables high drug loading for improved ADC potency. To highlight the benefits of ADC dual drug delivery, this strategy was applied to the preparation of ADCs containing two classes of auristatin drug‐linkers that have differing physiochemical properties and exert complementary anti‐cancer activities. Dual‐auristatin ADCs imparted activity in cell line and xenograft models that are refractory to ADCs comprised of the individual auristatin components. This work presents a facile method for construction of potent dual‐drug ADCs and demonstrates how delivery of multiple cytotoxic warheads can lead to improved ADC activities. Lastly, we anticipate that the conditions utilized herein for orthogonal cysteine unmasking are not restricted to ADCs and can be broadly utilized for site‐specific protein modification. John Wiley and Sons Inc. 2016-12-14 2017-01-16 /pmc/articles/PMC5299463/ /pubmed/27966822 http://dx.doi.org/10.1002/anie.201608292 Text en © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Communications
Levengood, Matthew R.
Zhang, Xinqun
Hunter, Joshua H.
Emmerton, Kim K.
Miyamoto, Jamie B.
Lewis, Timothy S.
Senter, Peter D.
Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title_full Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title_fullStr Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title_full_unstemmed Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title_short Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug Conjugates
title_sort orthogonal cysteine protection enables homogeneous multi‐drug antibody–drug conjugates
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299463/
https://www.ncbi.nlm.nih.gov/pubmed/27966822
http://dx.doi.org/10.1002/anie.201608292
work_keys_str_mv AT levengoodmatthewr orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT zhangxinqun orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT hunterjoshuah orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT emmertonkimk orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT miyamotojamieb orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT lewistimothys orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates
AT senterpeterd orthogonalcysteineprotectionenableshomogeneousmultidrugantibodydrugconjugates